<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84038">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01983449</url>
  </required_header>
  <id_info>
    <org_study_id>TSP0149</org_study_id>
    <secondary_id>1142183</secondary_id>
    <nct_id>NCT01983449</nct_id>
  </id_info>
  <brief_title>Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease</brief_title>
  <acronym>DANCE</acronym>
  <official_title>Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercator MedSystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercator MedSystems, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and effectiveness of adventitial deposition of the Study Drug in
      reducing inflammation and restenosis in patients with clinical evidence of claudication or
      critical limb ischemia and an angiographically significant lesion in the superficial femoral
      and/or popliteal arteries.

      Study Drug and Dose: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/ml, with dilute
      contrast (17%) administered to the adventitia in a dose of 1.6 mg per cm of desired vessel
      treatment length.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will examine the ability for adventitial dexamethasone to safely delay restenosis
      in patients at least 18 years of age, who have peripheral atherosclerotic lesions involving
      the superficial femoral and/or popliteal arteries. These patients have no current
      therapeutic alternatives beyond the procedure used to open, or revascularize, their
      superficial femoral and/or popliteal arteries. Metal stents have the potential to fracture
      when implanted in this artery segment due to continual flexion and bending of the knee. It
      is desirable to improve the patency of this artery after percutaneous transluminal
      angioplasty (PTA) and/or atherectomy-based revascularization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>MALE-POD</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acute safety safety outcomes will be determined by evaluating the type, frequency, severity, and relatedness of Major Adverse Limb Events or Peri-Operative Death (MALE+POD) within 30 days from the procedure for all subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duplex ultrasound index lesion binary restenosis</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Binary restenosis will be judged by core laboratory interpretation with peak systolic velocity ratio (PSVR) greater than 2.4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duplex ultrasound index lesion binary restenosis</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Binary restenosis will be judged by core laboratory interpretation with peak systolic velocity ratio (PSVR) greater than 2.4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term safety</measure>
    <time_frame>30 days to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Long term safety outcomes that occur after 30 days through 6 months post-procedure will be determined by evaluating adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duplex ultrasound index lesion flow limiting restenosis</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Flow limiting restenosis will be judged by core laboratory as PSVR&gt;4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory biomarkers</measure>
    <time_frame>Baseline and 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in inflammatory biomarkers will be measured with a panel of biomarkers in 1/3 of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular patency</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Target lesion revascularization (TLR) rate, target extremity revascularization (TER) rate, limb salvage rate and primary patency (PSVR≤2.4 and no TLR) at 6, 12, 18 and 24 months. Note: provisional stenting performed during the index procedure shall not be considered to be TLR, TER or loss of primary patency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome measures</measure>
    <time_frame>1, 6, 12, 18 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modified Walking Impairment Questionnaire, Ankle-Brachial Index, Rutherford Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion Technical Success</measure>
    <time_frame>Intraprocedural</time_frame>
    <safety_issue>No</safety_issue>
    <description>Distribution grade around infusion sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Intraprocedural</time_frame>
    <safety_issue>No</safety_issue>
    <description>Establishment of antegrade flow with residual stenosis of &lt;30% by angiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Economics</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of return visits and hospitalizations, time from index procedure to required revascularization and number of index-lesion-related readmissions within 30 days will be measured.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Peripheral Arterial Diseases</condition>
  <arm_group>
    <arm_group_label>Adventitial Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Sodium Phosphate Injection, USP</intervention_name>
    <description>Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.</description>
    <arm_group_label>Adventitial Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening Criteria

               -  Male or non-pregnant female ≥18 and ≤85 years of age

               -  Rutherford Clinical Category 2-4

               -  Resting ankle-brachial index (ABI) ≤ .90 (or in the event of non-compressible
                  vessels a toe-brachial index (TBI) of ≤ .80)

               -  Patient is willing to provide informed consent and comply with the required
                  follow up visits, testing schedule, and medication regimen

          -  Procedural Criteria

               -  De novo atherosclerotic lesion qualifying for angioplasty or atherectomy-based
                  revascularization

               -  &gt;70% diameter stenosis up to 15 cm in total length (with no greater than 3 cm
                  length of contiguous intervening normal artery) in the superficial femoral
                  and/or popliteal artery (between the profunda and tibioperoneal trunk)

               -  Reference vessel diameter ≥3 mm and ≤ 8mm

               -  Successful wire crossing of lesion

               -  A patent artery proximal to the index lesion free from significant stenosis
                  (significant stenosis defined as &gt;50% stenosis in iliac or &gt;30% stenosis in
                  common femoral artery) as confirmed by angiography (treatment of target lesion
                  after successful treatment of iliac or common femoral artery lesions is
                  acceptable)

        Exclusion Criteria:

          -  Screening Criteria

               -  Pregnant, nursing or planning on becoming pregnant in &lt; 2yrs

               -  Life expectancy of &lt;2 years

               -  Known active malignancy

               -  History of solid organ transplantation

               -  Patient actively participating in another investigational device or drug study

               -  History of hemorrhagic stroke within 3 months

               -  Previous or planned surgical or interventional procedure within 30 days of index
                  procedure

               -  Chronic renal insufficiency with eGFR &lt;29

               -  Prior bypass surgery, stenting, atherectomy or angioplasty of the target lesion

               -  Inability to take required study medications

               -  Contra-indication or known hypersensitivity to dexamethasone sodium phosphate,
                  contrast media, or antiplatelet regimen (5 days pre-op Plavix, 6 months post-op
                  Plavix, heparin or bivalirudin during intervention, protamine at end of
                  intervention if heparin was used, daily aspirin)

               -  Systemic fungal infection

               -  Anticipated use of IIb/IIIa inhibitor prior to index lesion treatment

               -  Acute or sub-acute thrombus, acute vessel occlusion or sudden symptom onset

               -  Acute limb ischemia

               -  Prior participation of the index limb in the current study (contralateral
                  treatment is allowed)

               -  Inability to ambulate (e.g. from prior ipsilateral or contralateral amputation)

               -  Patient is receiving steroids already

          -  Procedural Criteria

               -  Lesions extending into the trifurcation or above the profunda

               -  Heavy eccentric or moderate circumferential calcification at index lesion, which
                  in the judgment of the investigator would prevent penetration of the
                  Micro-Infusion Catheter needle through the vessel wall

               -  Lesion length is &gt;15 cm as measured from proximal normal vessel to distal normal
                  vessel, or there is no normal proximal arterial segment in which duplex
                  ultrasound velocity ratios can be measured

               -  Inadequate distal outflow defined as absence of at least one patent tibial
                  artery (no lesion &gt;50% stenosis) with flow into the foot

               -  Use of adjunctive therapies other than angioplasty, atherectomy or bare metal
                  stenting (i.e. laser, cryoplasty, scoring/cutting balloon, drug-eluting stent,
                  etc.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Owens, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmood Razavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Vascular Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen Poole, PhD</last_name>
    <email>kpoole@mercatormed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Heart Hospital / Abrazo Research / Tenant Health</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Osgood</last_name>
      <phone>602-602-5021</phone>
      <email>taosgood@abrazohealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Cardiovascular Research Foundation of Southern California</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirin Bhatia</last_name>
      <phone>310-275-9551</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Vascular Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Cloutier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CardioVascular Solutions Institute</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacey Bispham</last_name>
      <email>staceybispham@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Baptist</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Munroe Regional Medical Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rhonda Grubbs</last_name>
      <email>Rhonda@mediquestresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Fish</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Keith</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Vascular and Interventional</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Ft. Wayne</city>
        <state>Indiana</state>
        <zip>46802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheryl Bair</last_name>
      <email>cherylbairRN@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research of Northwest Indiana, LLC</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marsha Garvey</last_name>
      <phone>219-934-4200</phone>
      <phone_ext>251</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CardioVascular Assoc. / Louisiana Heart Hosp</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Candy Crespo</last_name>
      <phone>985-871-0735</phone>
      <phone_ext>145</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Willis Knighton Medical Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Wright</last_name>
      <phone>318-548-9908</phone>
      <email>swcrozier@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gail Kiddy</last_name>
      <email>Gail.A.Kiddy@medstar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Trovato</last_name>
      <email>mtrovato@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Wright</last_name>
      <email>Susan.Wright@stjohn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ. of Mississippi Med Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Lee</last_name>
      <phone>601-832-1001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.Louis University Hospital</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Craig Dedert</last_name>
      <email>cdedert@slu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wendy Aarnio</last_name>
      <phone>603-630-4763</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Dewey</last_name>
      <phone>609-893-1200</phone>
      <phone_ext>5023</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunterdon Medical Center</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaci Tyson</last_name>
      <phone>908-788-6471</phone>
      <phone_ext>267</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNC Health Care - REX</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Palermo</last_name>
      <phone>919-784-3795</phone>
      <email>Rebecca.Palermo@rexhealth.com</email>
    </contact>
    <investigator>
      <last_name>George Adams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OhioHealth</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Archer</last_name>
      <phone>614-566-1267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Felix</last_name>
      <phone>401-793-4105</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Polly Mock</last_name>
      <phone>512-421-3851</phone>
      <email>Polly.Mock@HCAhealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital Heart and Vascular Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Justus</last_name>
      <email>ElizabethJustus@texashealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DFW Vascular Group</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Egan</last_name>
      <phone>214-946-5165</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stone Oak Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Pruski</last_name>
      <phone>210-912-8180</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington Veterans Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Lewis</last_name>
      <email>lewiss@u.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracie Grainger</last_name>
      <email>tracie.granger@swedish.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adventitia</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Restenosis</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Anti-Inflammatory</keyword>
  <keyword>Dexamethasone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Sodium phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
